Advertisement
Screener

GERON CORP (GERN) Debt Securities, Available-for-sale, Current

2.8 / 5 stars · 68/120 Roast Me

GERON CORP Debt Securities, Available-for-sale, Current

GERON CORP (GERN) had Debt Securities, Available-for-sale, Current of $327.55 million as of 2024-12-31, per its 10-K filed 2025-02-27.

Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments

us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2025-02-27

  • 2024-12-31: Debt Securities, Available-for-sale, Current $327.55M.
  • 2024-09-30: Debt Securities, Available-for-sale, Current $279.43M.
  • 2024-06-30: Debt Securities, Available-for-sale, Current $245.79M.
  • 2024-03-31: Debt Securities, Available-for-sale, Current $253.29M.
Period endDebt Securities, Available-for-sale, Current
2024-12-31$327.55M
10-K · filed 2025-02-27
2024-09-30$279.43M
10-Q · filed 2024-11-07
2024-06-30$245.79M
10-Q · filed 2024-08-08
2024-03-31$253.29M
10-Q · filed 2024-05-02
2023-12-31$263.68M
10-K · filed 2025-02-27
2023-09-30$282.82M
10-Q · filed 2023-11-02
2023-06-30$314.48M
10-Q · filed 2023-08-03
2023-03-31$267.96M
10-Q · filed 2023-05-11
2022-12-31$115.90M
10-K · filed 2024-02-28
2022-09-30$133.68M
10-Q · filed 2022-11-07
2022-06-30$143.23M
10-Q · filed 2022-08-11
2022-03-31$135.34M
10-Q · filed 2022-05-09
2021-12-31$148.85M
10-K · filed 2023-03-16
2021-09-30$147.08M
10-Q · filed 2021-11-09
2021-06-30$140.96M
10-Q · filed 2021-08-16
2021-03-31$179.49M
10-Q · filed 2021-05-10
2020-12-31$186.35M
10-K · filed 2022-03-10
2020-09-30$182.67M
10-Q · filed 2020-11-05
2020-06-30$195.88M
10-Q · filed 2020-08-06
2020-03-31$111.82M
10-Q · filed 2020-05-28
2019-12-31$125.68M
10-K · filed 2021-03-11
2019-09-30$117.86M
10-Q · filed 2019-11-06
2019-06-30$134.78M
10-Q · filed 2019-08-01
2019-03-31$145.18M
10-Q · filed 2019-05-02
2018-12-31$152.71M
10-K · filed 2020-03-12
2018-09-30$153.62M
10-Q · filed 2018-11-01
2017-12-31$78.35M
10-K · filed 2019-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Faeth Therapeutics, Inc. (FTH)United States$0.750B